AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
All nine macaques given the control developed severe disease when exposed to bird flu, as did all given the smallest dose of ...
AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...
AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.
Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...
In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...
AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as a "growing global hub" for clinical trials. The C$820 million ...